Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Abstract Background Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the efficacy and safety of sarilumab + methotrexate (MTX) in Japanese patients w...

Full description

Bibliographic Details
Main Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham, Hideto Kameda
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Sarilumab
Japan
Phase III
Antibody
Anti-IL-6 receptor
Online Access:http://link.springer.com/article/10.1186/s13075-019-1856-4

Internet

http://link.springer.com/article/10.1186/s13075-019-1856-4

Similar Items